Regulatory mutations in human lipoprotein disorders and atherosclerosis

Current Opinion in Lipidology

Volumn 7, Issue 2, 1996, Pages 64-68

  Kontula, Kimmo ^a   Ehnholm, Christian ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; LIPID; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ATHEROSCLEROSIS; ENHANCER REGION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY; THROMBOSIS;

EID: 0029977225     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199604000-00003     Document Type: Short Survey

References (28)

1. Dammerman M, Breslow JL: Genetic basis of lipoprotein disorders. Circulation 1995, 91:505-512. An excellent, clinically oriented update on genes and dyslipidemias.
2. Cooper ON: Regulatory mutations and human genetic diseases. Ann Med 1992, 24:427-437.
3. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
4. Yokoama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993, 75:187-197.
5. Wang X, Sato R, Brown MS, Hua X, Goldstein JL: SREBP-1, a membranebound transcription factor released by sterol-regulated proteolysis. Cell 1994, 77:53-62. This hallmark paper introduces a novel and fundamental regulatory concept, whereby cellular cholesterol homeostasis is maintained.
6. Top B, Iotterlinden AG, van der Zee A, Kastelein JJP, Gevers Leuven JA, Havekes LM, Frants RR: Absence of mutations in the promoter region of the low density lipoprotein receptor gene in a large number of familial hypercholesterolemia patients as revealed by denaturing gradient gel electrophoresis. Hum Genet 1992, 89:561-565.
7. Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mut 1992, 1:445-466.
8. Koivisto U-M, Palvimo JJ, Jänne OA, Kontula K: A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia. Proc Natl Acad Sci USA 1994, 91:10526-10530. This paper describes the first FH-causing promoter substitution for which pathophysiological consequences have been verified.
9. Yang W-S, Nevin DN, Peng R, Brunzell JD, Deeb SS: A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci USA 1995, 92:4462-4466. The authors show convincingly that a single nucleotide substitution in the binding site of the transcription factor Oct-1 on the LPL gene promoter almost totally abolishes the promoter activity and results, when present in a heterozygous form, in a clinical phenotype of familial combined hyperlipidemia.
10. Dammerman M, Sandkuijl LA, Halaas JL, Chung WC, Breslow JL: An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993, 90:4562-4566.
11. Talmud PJ, Ye S, Humphries SE, on behalf of the EARS Group: Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study. Genet Epidemiol 1994, 11:265-280. An extensive survey comprising more than 1500 individuals from three different European nations shows an association between the APOA-I promoter polymorphism and serum A-I levels.
12. Saha N, Tay JSH, Low PS, Humphries SE: Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol 1994, 11:255-264.
13. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC: Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994, 35:1292-1296.
14. Smith JD, Brinton EA, Breslow JL: Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest 1992, 89:1796-1800.
15. Tuteja R, Tuteja N, Melo C, Casari G, Baralle FE: Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition. FEBS Lett 1992, 304:98-101.
16. Angotti E, Mele E, Costanzo F, Avvedimento EV: A polymorphism (G→A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency. J Biol Chem 1994, 269:17371-17374.
17. Miettinen HE, Korpela K, Hämäläinen L, Kontula K: Polymorphisms of the apolipoprotein and angiotensin converting enzyme genes in young North Karelian patients with coronary heart disease. Hun Genet 1994, 94:189-192.
18. Lopez-Miranda J, Ordovas JM, Espino A, Marin C, Salas J, Lopez-Segura F, Jimenez-Pereperez J, Perez-Jimenez F: Influence of mutation in human apolipoprotein A-I promoter on plasma LDL cholesterol response to dietary fat Lancet 1994, 343:1246-1249.
19. Utermann G, Haibach C, Trommsdorff M, Kochl S, Lingenhel A, Abe A, Kragt HG: Genetic architecture of the atherogenic lipoprotein (a). Ann N Y Acad Sci 1995, 748:301-312. A superb review of the molecular biology of Lp(a), providing condensed information on the contribution of common genetic polymophisms of apo(a) on circulating Lp(a) levels.
20. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM: 5′ control regions of the apolipoprotein (a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 1993, 90:1369-1373.
21. Bopp S, Kochl S, Acquati F, Magnaghi P, Petho-Schramm A, Kraft H-G, Utermann G, Muller H-J, Taramelli R: Ten allelic apolipoprotein (a) 5′ flanking fragments exhibit comparable promoter activities in HepG2 cells. J Lipid Res 1995, 36:1721-1728.
22. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM: C/T polymorphism in the 5′ untranslated region of the apolipoprotein (a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995, 15:58-64. The nucleotide T instead of C is present at position +93 in the APO(a) gene promoter in approximately one out of seven individuals. Although not affecting the transcription rate, this variant results in diminished translation of the APO(a) mRNA into a mature protein.
23. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557-1563.
24. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993, 268:10739-10745.
25. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocarcial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855. The 4G allele of the insertion/deletion polymorphism in the PAI(-1) promoter is associated with higher plasma PAI(-1) activity and myocardial infarction. The lower promoter activity of the 5G allele is proposed to be caused by its ability to bind a nuclear repressor protein.
26. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995, 44:37-42.
27. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995, 73:209-215.
28. Spek CA, Koster T, Rosendaal FR, Berina RM, Reitsma PH: Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995, 15:214-218.